Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Objective: 

To evaluate the relationships between dose, plasma concentration, pharmacological activity and clinical outcome to evaluate the appropriateness of therapeutic drug monitoring (TDM) in patients receiving amisulpride. Method: 

Literature search of Embase, Medline and PubMed databases. Results: 

Amisulpride plasma concentration is closely correlated with dose (r2 = 0.96, P < 0.0001), dopamine occupancy, response and with extra-pyramidal symptoms (EPS). Dose is correlated with response, dopamine occupancy and EPS. Optimal clinical response was found at doses of 400–800 mg/day, corresponding to plasma levels of approximately 200–500 ng/ml. EPS appears to be more reliably predicted by a plasma level above 320 ng/ml than by a particular dose. Conclusion: 

The effects and safety of amisulpride in the treatment of schizophrenia and schizoaffective disorder are predicted by daily dose. The plasma concentration threshold for response appears to be approximately 200 ng/ml. EPS are more reliably predicted by plasma level than by dose. TDM for patients prescribed amisulpride is thus of some clinical value.

Keywords: amisulpride; plasma concentration; plasma level; therapeutic drug monitoring

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0447.2009.01429.x

Affiliations: 1: Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill 2: Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, De Crespigny Park, London, UK

Publication date: December 1, 2009

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more